|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
13
|
|
pubmed:dateCreated |
2004-8-18
|
|
pubmed:abstractText |
Hepatic decompensation was reported from two recent trials (APRICOT and RIBAVIC) assessing interferon (IFN)-based treatment of hepatitis C virus (HCV) in HIV/HCV-coinfected patients. This paper identifies risk factors associated with hepatic decompensation in APRICOT.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0269-9370
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
3
|
|
pubmed:volume |
18
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
F21-5
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:15316334-Antiviral Agents,
pubmed-meshheading:15316334-Drug Therapy, Combination,
pubmed-meshheading:15316334-HIV Infections,
pubmed-meshheading:15316334-Hepatitis C, Chronic,
pubmed-meshheading:15316334-Humans,
pubmed-meshheading:15316334-Interferon-alpha,
pubmed-meshheading:15316334-Liver Cirrhosis,
pubmed-meshheading:15316334-Liver Failure,
pubmed-meshheading:15316334-Polyethylene Glycols,
pubmed-meshheading:15316334-Recombinant Proteins,
pubmed-meshheading:15316334-Ribavirin,
pubmed-meshheading:15316334-Risk Factors
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy.
|
|
pubmed:affiliation |
Center for HIV and Hepatogastroenterology, Düsseldorf, Germany.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|
